Michael Pourdehnad

Title(s)Volunteer Assistant Clinical Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator. CPT Pharmacometrics Syst Pharmacol. 2023 10; 12(10):1473-1484. Wu F, Liu L, Gaudy A, Wang X, Carayannopoulos L, Pourdehnad M, Lamba M. PMID: 37705327; PMCID: PMC10583261.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    2. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Sep 14; 389(11):1009-1022. Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ, CC-92480-MM-001 Study Investigators. PMID: 37646702.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    3. Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. EJHaem. 2022 May; 3(2):394-405. Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V. PMID: 35846031; PMCID: PMC9175947.
      View in: PubMed   Mentions: 4  
    4. Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies. AAPS J. 2022 Jan 14; 24(1):29. Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV. PMID: 35038051; PMCID: PMC9172776.
      View in: PubMed   Mentions:    Fields:    
    5. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. EJHaem. 2022 Feb; 3(1):139-153. Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. PMID: 35846221; PMCID: PMC9176062.
      View in: PubMed   Mentions: 3  
    6. Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies. AAPS J. 2021 08 27; 23(5):103. Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV. PMID: 34453265; PMCID: PMC8397660.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    7. Population Pharmacokinetics of CC-122. Clin Pharmacol. 2021; 13:61-71. Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y. PMID: 33958900; PMCID: PMC8093142.
      View in: PubMed   Mentions:
    8. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 02 25; 64(4):1835-1843. Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, Lu G, LeBrun LA, Cathers BE, Zhang W, Tang Y, Ammirante M, Narla RK, Piccotti JR, Pourdehnad M, Lopez-Girona A. PMID: 33591756.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    9. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 02 04; 137(5):661-677. Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen J, Wang JCY, Minden MD, Fan J, Pierce DW, Pourdehnad M, Rolfe M, Lopez-Girona A, Dick JE, Lu G. PMID: 33197925; PMCID: PMC8215192.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    10. Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. Cancer Sci. 2021 Jan; 112(1):331-338. Hatake K, Chou T, Doi T, Terui Y, Kato H, Hirose T, Seo S, Pourdehnad M, Ogaki Y, Fujimoto H, Hagner PR, Yamamoto K. PMID: 33075165; PMCID: PMC7780008.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    11. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol. 2020 Sep; 7(9):e649-e659. Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V. PMID: 32758434.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    12. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020 03 26; 135(13):996-1007. Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. PMID: 31977002; PMCID: PMC7099331.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    13. Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent. Blood. 2020 03 26; 135(13):1008-1018. Risueño A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, Pourdehnad M, Gandhi AK, Trotter MWB. PMID: 31977005; PMCID: PMC7099333.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    14. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 01 01; 25(1):90-98. Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J, Shih K. PMID: 30201761.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    15. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015 Aug 06; 126(6):779-89. Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK. PMID: 26002965; PMCID: PMC4528065.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    16. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11988-93. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. PMID: 23803853; PMCID: PMC3718086.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansAnimalsCells
    17. Investigating Myc-dependent translational regulation in normal and cancer cells. Methods Mol Biol. 2013; 1012:201-12. Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D. PMID: 24006066; PMCID: PMC4390065.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    18. Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET. Hell J Nucl Med. 2011 Sep-Dec; 14(3):219-23. Pourdehnad M, Basu S, Duarte P, Okpaku AS, Saboury B, Hustinx R, Alavi A. PMID: 22087438.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Stability of cerebral blood flow measures using a split-dose technique with (99m)Tc-exametazime SPECT. Nucl Med Commun. 2005 May; 26(5):475-8. Newberg AB, Saffer J, Farrar J, Pourdehnad M, Alavi A. PMID: 15838432.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging. 2005 Jul; 32(7):749-56. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S. PMID: 15785956.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    21. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am. 2005 Jan; 43(1):35-47. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PMID: 15693646.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansPHPublic Health
    22. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004 May; 68(1):1-9. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS. PMID: 15174514.
      View in: PubMed   Mentions: 49     Fields:    Translation:Animals
    23. Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents. Nucl Med Biol. 2004 May; 31(4):483-91. Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, Schirrmacher R, Vatamaniuk M, Doliba N, Matschinsky F, Wolf B, Rösch F, Naji A, Alavi AA. PMID: 15093819.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    24. Cerebral blood flow during meditative prayer: preliminary findings and methodological issues. Percept Mot Skills. 2003 Oct; 97(2):625-30. Newberg A, Pourdehnad M, Alavi A, d'Aquili EG. PMID: 14620252.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    25. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001 Oct; 22(10):1123-8. Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, Lee JH, Loman JC, Rossman MD, Alavi A. PMID: 11567186.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    26. Inter-modality comparisons of seizure focus lateralization in complex partial seizures. Eur J Nucl Med. 2001 Oct; 28(10):1529-40. Meyer PT, Cortés-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, Alavi A. PMID: 11685497.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001 Sep; 42(9):1412-7. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A. PMID: 11535734.
      View in: PubMed   Mentions: 174     Fields:    Translation:HumansAnimalsCells
    28. Similar pelvic abnormalities on FDG positron emission tomography of different origins. Clin Nucl Med. 2001 Jun; 26(6):515-7. Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A. PMID: 11353298.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection. Clin Nucl Med. 2001 May; 26(5):458. Zhuang H, Pourdehnad M, Yamamoto AJ, Rossman MD, Alavi A. PMID: 11317033.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. The measurement of regional cerebral blood flow during the complex cognitive task of meditation: a preliminary SPECT study. Psychiatry Res. 2001 Apr 10; 106(2):113-22. Newberg A, Alavi A, Baime M, Pourdehnad M, Santanna J, d'Aquili E. PMID: 11306250.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    31. The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001 Jan; 42(1):44-8. Zhuang H, Duarte PS, Pourdehnad M, Maes A, Van Acker F, Shnier D, Garino JP, Fitzgerald RH, Alavi A. PMID: 11197979.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    32. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000 Sep; 21(9):793-8. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. PMID: 11065150.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    33. 26. Incidental findings should be included in the analysis of cost-effectiveness for evaluation of pulmonary nodules by FDG-PET. Clin Positron Imaging. 2000 Jul; 3(4):180. Zhuang HM, Duarte P, Pourdehnad M, Yamamoto AJ, Loman JC, Sinha P, Alavi A. PMID: 11150783.
      View in: PubMed   Mentions: 1  
    34. Gastric emptying of solids: estimates of lag phase and constant emptying times. Nucl Med Commun. 2000 Jul; 21(7):665-75. Couturier O, Le Rest C, Gournay J, Pourdehnad M, Bridji B, Turzo A, Bizais Y. PMID: 10994671.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    35. Standardized uptake value as an unreliable index of renal disease on fluorodeoxyglucose PET imaging. Clin Nucl Med. 2000 May; 25(5):358-60. Zhuang H, Duarte PS, Pourdehnad M, Li P, Alavi A. PMID: 10795695.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender. Am J Physiol. 1999 03; 276(3):R707-14. Teff KL, Alavi A, Chen J, Pourdehnad M, Townsend RR. PMID: 10070130.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    37. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer. Int J Oncol. 1999 Feb; 14(2):233-44. Cesano A, Wortman JA, Pourdehnad M, Visonneau S, Mozley D, Bhatnagar A, Alavi A, Santoli D. PMID: 9917497.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    Michael's Networks
    Concepts (222)
    Derived automatically from this person's publications.
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _